Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Tango Therapeutics, Inc. | General Counsel | Common Stock | 66K | $209K | $3.16 | Feb 5, 2025 | Direct |
Tango Therapeutics, Inc. | General Counsel | Stock Option (Right to Buy) | 164K | Feb 3, 2025 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TNGX | Tango Therapeutics, Inc. | Feb 4, 2025 | 2 | -$16.4K | 4 | Feb 6, 2025 | General Counsel |
TNGX | Tango Therapeutics, Inc. | Feb 3, 2025 | 2 | $0 | 4 | Feb 5, 2025 | General Counsel |
TNGX | Tango Therapeutics, Inc. | Feb 6, 2024 | 2 | -$35K | 4 | Feb 8, 2024 | General Counsel |
TNGX | Tango Therapeutics, Inc. | Feb 1, 2024 | 2 | $0 | 4 | Feb 5, 2024 | General Counsel |
TNGX | Tango Therapeutics, Inc. | Mar 1, 2023 | 2 | $0 | 4 | Mar 2, 2023 | General Counsel |
TNGX | Tango Therapeutics, Inc. | Feb 1, 2022 | 1 | $0 | 4 | Feb 3, 2022 | General Counsel |
TNGX | Tango Therapeutics, Inc. | Oct 14, 2021 | 0 | $0 | 3 | Nov 1, 2021 | General Counsel, Corporate Secretary |